Lakefront Biotherapeutics NV LKFT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | -311.54M | -309.91M |
| Total Depreciation and Amortization | -- | -- | -- | 21.49M | 62.35M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 6.31M |
| Total Other Non-Cash Items | -- | -- | -- | 74.10M | 72.23M |
| Change in Net Operating Assets | -- | -- | -- | -128.81M | -137.27M |
| Cash from Operations | -- | -- | -- | -297.59M | -306.30M |
| Capital Expenditure | -- | -- | -- | -20.14M | -20.51M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 3.20K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 4.60M | 4.26M |
| Other Investing Activities | -- | -- | -- | 319.47M | 325.27M |
| Cash from Investing | -- | -- | -- | 303.93M | 309.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -4.30M | -4.30M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -4.54M | -4.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -2.46M | -2.44M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | -652.90K | -4.37M |